*Some Market data delayed by 15 mins.

NexImmune, Inc. Common Stock

Symbol: NEXI (NASDAQ)
3.60 ▲ (4.96%) 0.170

Company Description:
NexImmune Inc is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's T cells to generate an antigen-specific cell-mediated immune response with curative potential for the patient. It creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. The company has two product candidates in human trials: NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM.

Key Stats
  • Today's Open: $3.615
  • Today's High: $3.615
  • Today's Low: $3.6
  • Today's Volume: 130
  • Yesterday Close: $3.43
  • Yesterday High: $3.59
  • Yesterday Low: $3.43
  • Yesterday Volume: 6.79K
  • Last Min Volume: 38
  • Last Min High: $3.6
  • Last Min Low: $3.6
  • Last Min VWAP: $3.6
Company Profile
  • Name: NexImmune, Inc. Common Stock
  • Website: https://www.neximmune.com
  • Listed Date: 2021-02-12
  • Location: GAITHERSBURG, MD
  • Market Status: Active
  • CIK Number: 0001538210
  • SIC Code: 2834
  • SIC description: PHARMACEUTICAL PREPARATIONS
  • Market Cap: $4.70M
  • Round Lot: 100
  • Outstanding Shares: 1.37M
  • Asset Type: CS
RECENT FILINGS FOR NEXI
Filing DateFiling TypeFormat
2024-04-1610-KView
2024-04-103View
2024-04-058-KView
2024-03-29NT 10-KView
2024-02-06DEFA14AView
2024-02-058-KView
2024-02-05424B5View
2024-02-028-KView
2024-02-018-KView
2024-01-198-KView
2024-01-18DEFA14AView
2023-12-228-KView
2023-12-018-KView
2023-11-22144/AView
2023-11-22144/AView
2023-11-224View
2023-11-21144View
2023-11-20DEF 14AView
2023-11-208-K/AView
2023-11-1710-QView
Latest News

 

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money. Copyright© 2024, 247MarketNews inc.